Odyssey Therapeutics (NASDAQ:ODTX) Now Covered by Analysts at Raymond James Financial

Equities researchers at Raymond James Financial assumed coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a report released on Thursday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $42.00 price target on the stock. Raymond James Financial’s target price would suggest a potential upside of 121.05% from the stock’s previous close.

ODTX has been the subject of several other research reports. JPMorgan Chase & Co. boosted their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings started coverage on shares of Odyssey Therapeutics in a research report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. Wall Street Zen downgraded Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Oppenheimer restated an “outperform” rating and issued a $40.00 target price on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Finally, HC Wainwright assumed coverage on Odyssey Therapeutics in a report on Thursday, August 27th. They issued a “buy” rating and a $44.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.00.

Odyssey Therapeutics Stock Performance

Shares of ODTX traded up $0.88 during midday trading on Thursday, hitting $19.00. 325,591 shares of the company traded hands, compared to its average volume of 427,235. The stock has a market cap of $913.14 million and a PE ratio of -2.81. Odyssey Therapeutics has a 52 week low of $15.10 and a 52 week high of $29.05. The firm has a 50 day simple moving average of $22.76.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, equities analysts anticipate that Odyssey Therapeutics will post -6.20 EPS for the current year.

Institutional Investors Weigh In On Odyssey Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in shares of Odyssey Therapeutics in the second quarter worth $4,162,000. State Street Corp purchased a new position in shares of Odyssey Therapeutics during the 2nd quarter valued at $1,477,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Odyssey Therapeutics during the 2nd quarter valued at about $601,000.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.